Key result
Long-term treatment with low-molecular-weight heparin was as effective as vitamin K antagonists in preventing recurrent VTE across 11 trials and reduced recurrence in cancer patients in 2 studies.
Why the study?
Does long-term treatment with LMWH compared to VKAs reduce recurrent VTE and post-thrombotic syndrome in patients with DVT, including those with cancer?
Population
Patients with deep-vein thrombosis, including a broad spectrum of patients and a specific subgroup of…
Comparison
Low-molecular-weight heparin for long-term… vs Vitamin K antagonists (VKAs)
Design
Review
Follow-up
long-term
Authors
Loading...
May favor LMWH for cancer-associated VTE; leaves open post-thrombotic syndrome benefits in broader populations.
Does long-term treatment with LMWH compared to VKAs reduce recurrent VTE and post-thrombotic syndrome in patients with DVT, including those with cancer?
Long-term LMWH is as effective as VKAs for preventing recurrent VTE in broad DVT populations, more effective in cancer patients, and may reduce the risk of post-thrombotic syndrome.
Townshend et al. (2013) conducted a review in deep-vein thrombosis (DVT). low-molecular-weight heparin (LMWH) vs. vitamin K antagonists (VKAs) was evaluated on recurrent venous thromboembolism (VTE). Long-term treatment with low-molecular-weight heparin was as effective as vitamin K antagonists in preventing recurrent VTE across 11 trials and reduced recurrence in cancer patients in 2 studies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: